var title_f13_62_14304="Laparoscopic transcystic bile duct exploration";
var content_f13_62_14304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic transcystic bile duct exploration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laparoscopic transcystic bile duct exploration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Maier, RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14304=[""].join("\n");
var outline_f13_62_14304=null;
var title_f13_62_14305="ERCP ascaris infestation";
var content_f13_62_14305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Ascaris infestation of the bile duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Contrast injected into the papilla of vater shows ascaris worms obstructing the common bile duct and impinging on the main pancreatic duct. B) The worms are removed using a tripod basket.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright &copy;1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14305=[""].join("\n");
var outline_f13_62_14305=null;
var title_f13_62_14306="Lactase: Drug information";
var content_f13_62_14306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lactase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lac-Dose&reg; [OTC];",
"     </li>",
"     <li>",
"      Lactaid&reg; Fast Act [OTC];",
"     </li>",
"     <li>",
"      Lactaid&reg; Original [OTC];",
"     </li>",
"     <li>",
"      Lactose Intolerance [OTC];",
"     </li>",
"     <li>",
"      Lactrase&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dairyaid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactose intolerance: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: 1-2 capsules taken with milk or meal; pretreat milk with 1-2 capsules/quart of milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid: 5-15 drops/quart of milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 1-3 tablets with meals",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 3000 FCC lactase units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactaid&reg; Fast Act: 9000 FCC lactase units [contains sodium 5 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactaid&reg; Original: 3000 FCC lactase units [contains sodium 1.67 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactrase&reg;: 250 mg standardized enzyme lactase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactose Intolerance: 250 mg standardized enzyme lactase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 9000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lac-Dose&reg;: 3000 FCC lactase units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactaid&reg; Fast Act: 9000 FCC lactase units [contains sodium 5 mg/tablet; vanilla twist flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Help digest lactose in milk for patients with lactose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F186370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lactrase Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $77.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Lactaid Fast Act Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9000 unit (32): $7.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Lactaid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4500 unit (50): $6.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lac-Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3000 unit (50): $5.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lactaid Fast Act Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9000 unit (32): $7.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lactaid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3000 unit (120): $11.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lactaid Ultra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9000 unit (32): $6.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Milk Digestant Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-2 mg (200): $8.35",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Enzym laktaza (PL);",
"     </li>",
"     <li>",
"      Lactosanol (PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9531 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14306=[""].join("\n");
var outline_f13_62_14306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186373\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186374\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186379\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186375\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186376\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186366\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186360\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186367\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299565\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221194\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186370\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323268\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186371\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_62_14307="Mitomycin (ophthalmic): Patient drug information";
var content_f13_62_14307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mitomycin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/33/532?source=see_link\">",
"     see \"Mitomycin (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14624261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mitosol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13914461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during eye surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13914460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mitomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13914463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13914464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13914465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13914462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13914466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13914467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83357 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14307=[""].join("\n");
var outline_f13_62_14307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14624261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914461\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914460\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914463\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914464\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914465\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914462\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914466\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13914467\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/33/532?source=related_link\">",
"      Mitomycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28166?source=related_link\">",
"      Mitomycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10773?source=related_link\">",
"      Mitomycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_62_14308="Thymoma CT I";
var content_f13_62_14308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73685%7EPULM%2F50638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73685%7EPULM%2F50638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of a thymoma originating from the right lobe of the thymus. A large rounded mass is seen in the retrosternal location, to the right of the midline (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thymoma originating from the left lobe of the thymus. There is a large rounded inhomogeneous retrosternal mass located to the left of the midline (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14308=[""].join("\n");
var outline_f13_62_14308=null;
var title_f13_62_14309="The autonomic ganglia in the retroperitoneum";
var content_f13_62_14309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    The autonomic ganglia in the retroperitoneum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Innervation of the adrenal glands is via visceral afferent fibers arising from the celiac, aorticorenal, and renal ganglia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14309=[""].join("\n");
var outline_f13_62_14309=null;
var title_f13_62_14310="HS Crohns1";
var content_f13_62_14310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease mimicking hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14310=[""].join("\n");
var outline_f13_62_14310=null;
var title_f13_62_14311="Gastric carcinoid poorly diff";
var content_f13_62_14311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poorly differentiated gastric carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a gastric carcinoid reveals sheets of poorly differentiated tumors cells with areas of necrosis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14311=[""].join("\n");
var outline_f13_62_14311=null;
var title_f13_62_14312="Pathogenesis of delayed gastric emptying";
var content_f13_62_14312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of delayed gastric emptying",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Michael Camilleri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14312/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/62/14312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal gastrointestinal motor function is a complex sequence of events that is controlled by an extrinsic nerve supply from the brain and spinal cord, the complex plexi within the wall of the stomach and intestine (the enteric brain), and the effects of locally released transmitters, such as amines and peptides, that alter the excitability of the smooth muscle of the intestine. Abnormalities in any of these locations can lead to delayed gastric emptying (gastric stasis), a disorder which is often expressed clinically as nausea, vomiting, early or easy satiety, bloating, and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal physiology of gastric motor function and the pathogenesis of delayed gastric emptying will be reviewed here. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .) The American Gastroenterological Association (AGA) technical review for the diagnosis and treatment of gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY OF GASTRIC MOTOR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the pathogenesis of delayed gastric emptying requires comprehension of the physiology of normal gastric motor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Control of gut motor function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motor function of the gut is controlled at three main levels (",
"    <a class=\"graphic graphic_figure graphicRef55162 \" href=\"UTD.htm?0/51/817\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Parasympathetic and sympathetic nervous systems",
"     </li>",
"     <li>",
"      Enteric neurons",
"     </li>",
"     <li>",
"      Smooth muscle cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Autonomic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrinsic neural control by parasympathetic pathways is conveyed to the stomach and upper intestine through the vagus nerves. Vagal efferents arise in the dorsal motor nucleus of the vagus nerve and, to a lesser extent, from the nucleus ambiguus and tractus solitarius. They form characteristic bead-chain-like terminals in the myenteric plexus throughout the stomach but do not directly innervate muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sympathetic supply reaches the stomach from the intermediolateral columns of the spinal cord at the T5 to T10 levels via the celiac ganglia. Splanchnic efferents to the stomach have cell bodies in the celiac ganglia; they supply the myenteric ganglia, give a few fibers to nonsphincteric muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/4\">",
"     4",
"    </a>",
"    ], and densely supply the pyloric sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Splanchnic efferents innervating blood vessels contain norepinephrine and neuropeptide Y; those innervating the submucous ganglia and circular muscle contain norepinephrine and somatostatin; and fibers to the myenteric ganglia contain only norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Enteric nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enteric nervous system constitutes a vast network of ganglionated plexi that serves as the integrative circuitry between extrinsic modulation of gastrointestinal motility (via the sympathetic and parasympathetic nervous system), and sensory afferents in the gastric wall (stimulated by luminal stimuli). These neuronal networks, or plexi, are organized in five layers which are interspersed throughout the wall of the gut; the best characterized are the myenteric, deep muscular, and submucosal plexi.",
"   </p>",
"   <p>",
"    The deep muscular plexus is made up of the interstitial cells of Cajal, pacemakers for the sheets of muscle within the wall of the gut. These neurons may contain more than one transmitter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/8\">",
"     8",
"    </a>",
"    ]. They are the neural plexi involved in propulsion, the interdigestive migrating motor complex, sensation, and secretion. The most common gastric cellular defects in gastroparesis are loss of expression of neuronal nitric oxide (nNOS) and interstitial cells of Cajal (ICC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide (NO) regulation may be important in gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. NO synthase was reduced in a murine model of diabetic gastropathy and was restored with insulin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Smooth muscle cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third level of control of gastrointestinal motility is in the excitable membrane of smooth muscle cells. Specific receptors in the cell membrane bind to amines, peptides, and other transmitters that reach the smooth muscle membrane via neurocrine, endocrine, or paracrine routes. Pacemaker cells which are characterized by spontaneous depolarization of the resting membrane potential fire action potentials that contract the cell. Electrical coupling of the neighboring muscle cells, organized in a syncytium, results in the spread of the contraction around the circumferential and longitudinal axes of the stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peristaltic reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peristaltic reflex is responsible for propulsion of food from the stomach into the intestine. There are two components to the peristaltic reflex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first change is ascending contraction above the level of luminal stimulation, usually due to distention by a food bolus. The main transmitters involved in excitation of gastric muscle are acetylcholine (and, indirectly, serotonin through 5HT4 receptors located on cholinergic interneurons) and tachykinins, such as substance P and substance K.",
"     </li>",
"     <li>",
"      Descending inhibition below the level of distention is essential for the oncoming bolus to encounter a minimum of resistance to flow. The main inhibitory transmitters are nitric oxide and vasoactive intestinal peptide (VIP), although several other transmitters modulate the interneurons involved in this descending inhibitory pathway, including opiates, somatostatin, and the excitatory transmitter, gamma-aminobutyric acid [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Motor functions of the stomach regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach muscle has three muscular layers with fibers organized in different axes: circular, oblique, and longitudinal. The stomach has traditionally been regarded as having two functional segments: the fundus and the antrum. The mid-portion of the greater curvature of the stomach is the functional site of the gastric electrical pacemaker.",
"   </p>",
"   <p>",
"    During fasting, the stomach participates in the cyclical activity front that propagates through the gastrointestinal tract and serves as a \"housekeeper,\" propelling nondigestible solid residue towards the colon. There is some evidence in dogs that the hormone motilin, released from the duodenal loop, stimulates this gastric component of the migrating motor complex [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/13\">",
"     13",
"    </a>",
"    ]. Laboratory based studies in healthy humans suggest that only about 50 percent of intestinal migrating motor complexes during fasting are associated with an antral component [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This may reflect the efficiency of antral contractions during phase III of the migrating motor complex in clearing nondigestible solids from the stomach.",
"   </p>",
"   <p>",
"    Postprandially, the fundus relaxes during swallowing to start the process of accommodation in which the stomach assumes reservoir functions, facilitating the initial chemical digestion of food by acid and proteases before transfer toward the antrum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/16\">",
"     16",
"    </a>",
"    ]. The antrum produces high amplitude contractions that pulverize solids by physical and liquid shearing forces. Once solids have been reduced in size to particles of 1 to 2 mm in size (trituration), they are able to empty through the pylorus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/17\">",
"     17",
"    </a>",
"    ]. Larger particles are repetitively propelled and retropulsed from the distal stomach by an occluded gastric outlet segment until liquid shearing and chemical digestion achieve trituration.",
"   </p>",
"   <p>",
"    Thus, antral motor function is critical for the grinding, mixing, and emptying of solids from the stomach. Antral motility also significantly correlates with the rate of emptying of liquids from the stomach, after the lag time required for trituration to sufficiently reduce particle size so that pyloric sieving is no longer required [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/18\">",
"     18",
"    </a>",
"    ]. Interdigestive (between meals) antral motor function clears the stomach of undigestible solid particles whose size has not been reduced by trituration (",
"    <a class=\"graphic graphic_figure graphicRef80945 \" href=\"UTD.htm?2/37/2645\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The recovery of proximal gastric tone during the postprandial period is associated with gastric emptying, with the driving force being provided by the pressure gradient between the stomach and duodenum. Most non-nutrient liquids have emptied before tone is restored to normal, suggesting that emptying of liquids may be partly a passive process aided by gravity and the absence of resistance in the gastric outlet.",
"   </p>",
"   <p>",
"    The pylorus is radiologically 0.6 to 1.6 cm long. It presents functionally as a zone of high resting pressure or tone, upon which are superimposed phasic contractions at a rate of three per minute. These contractions sweep across the antroduodenal junction. There is evidence of control of pyloric contractions by opiates, acetylcholine, and nitric oxide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF DELAYED GASTRIC EMPTYING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several abnormalities that may result in motor dysfunction of the stomach and thereby in delayed gastric emptying. Each of the stomach regions may be affected by different pathologic processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormalities of the fundus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several diseases that are associated with abnormal proximal gastric motor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postvagotomy gastric motor dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach's accommodation response and phasic contractility in response to distention are abolished following vagotomy and partial gastric resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/16\">",
"     16",
"    </a>",
"    ]. This probably accounts for the observation that there is immediate early transfer of the liquid phase of the meal to the distal stomach and beyond, but delayed emptying of solids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/19\">",
"     19",
"    </a>",
"    ]. One of the most common causes of impaired fundal accommodation is fundoplication; the impaired relaxation may be aggravated by concomitant vagal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes mellitus have difficulties with antral motor function and coordination (see",
"    <a class=\"local\" href=\"#H14\">",
"     'The antrum and antroduodenal coordination'",
"    </a>",
"    below), and show evidence of abnormal postprandial proximal gastric accommodation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/21\">",
"     21",
"    </a>",
"    ] and contraction. One study, for example, evaluated eight patients with type 1 diabetes, cardiovascular autonomic neuropathy, and dyspepsia, and 10 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/22\">",
"     22",
"    </a>",
"    ]. Blood glucose levels were maintained in the normal range during the experiment. An intragastric bag connected to a barostat was inflated and deflated by stepwise pressure increments, creating pressure volume curves. There was a larger volume during the pressure increase in the diabetics than in the controls; this resulted in a significant difference in compliance",
"    <span class=\"nowrap\">",
"     (dV/dP):",
"    </span>",
"    57.2",
"    <span class=\"nowrap\">",
"     mL/mmHg",
"    </span>",
"    in diabetics versus 43.7",
"    <span class=\"nowrap\">",
"     mL/mmHg",
"    </span>",
"    in controls. In addition, gastric distension induced more nausea, bloating, and upper abdominal pain in the patients than the volunteers. The post-meal relaxation response of the stomach is quite variable even in patients with evidence of cardiovagal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]; experimental data also suggest that adaptive mechanisms may restore gastric relaxation to normal after vagal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/25\">",
"     25",
"    </a>",
"    ]. These observations may explain the unpredictability of the motor abnormalities over time in patients with diabetic gut dysmotility.",
"   </p>",
"   <p>",
"    Increased compliance may explain the prolongation of lag time for emptying solids that is observed in patients with diabetes. Solids are selectively retained within the stomach during this time, often in the proximal compartment. Increased fundic contractions are responsible for accelerated gastric emptying of liquids in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate gastric accommodation in diabetes may be due to a defective nitric oxide pathway. In one study, for example, gastric relaxation was impaired in rats mainly by decreased expression of nitric oxide synthase in the gastric myenteric plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Motility disturbances in functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional dyspepsia (also called nonulcer or motility-like dyspepsia) is a disorder in which patients complain predominantly of nausea, early satiety, postprandial fullness, bloating, and pain without obvious evidence of organic disease (eg, by upper endoscopy or upper gastrointestinal studies). Gastric compliance is lower in patients with motility-like dyspepsia than in healthy controls, an abnormality that may contribute to the associated symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/20,28\">",
"     20,28",
"    </a>",
"    ]. Reduced compliance was associated with significant weight loss in another report, suggesting that it resulted in early satiety and reduced food intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/29\">",
"     29",
"    </a>",
"    ]. A summary of the motor and sensory dysfunctions reported in the literature in nonulcer dyspepsia is shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef78572 \" href=\"UTD.htm?42/44/43716\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/30\">",
"     30",
"    </a>",
"    ]. Disturbances in proximal gastric function (accommodation or a reduced gastric volume response to feeding, and gastric hypersensitivity) have also been described in children with dyspepsia or chronic functional abdominal pain that may result in similar symptoms to those that result in impaired gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, there is a clear association with acute onset and a febrile illness suggesting the possibility that dyspepsia is a post-infectious or post-inflammatory disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/33\">",
"     33",
"    </a>",
"    ]. Such patients appear to have the same sensory or motor disorders that characterize the pathophysiology of other dyspeptic patients who do not report this acute onset with a febrile illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The antrum and antroduodenal coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, antral motor function is critical for the grinding, mixing, and emptying of solids from the stomach. Thus, in the absence of well-coordinated antral interdigestive motor function, as in the postvagotomy state or in diabetic autonomic neuropathy, undigestible solid particles may accumulate over time and eventually form a bezoar.",
"   </p>",
"   <p>",
"    Abnormalities of antral function can occur by several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decreased frequency of antral contractions is the most common form of gastric motor dysfunction; this is associated with a reduced rate of gastric emptying in patients with gastroparesis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/34\">",
"       34",
"      </a>",
"      ]. In neuropathic disorders, this is usually manifested by a lower frequency of distal antral contractions &gt;40 mmHg in response to a meal. Thus, the frequency averages 0.5 to 0.75 per minute in neuropathic diseases versus 1 per minute in healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced antral contractile amplitude is rarely observed in infiltrative disorders such as progressive systemic sclerosis. The average amplitude of contractions is typically less than 40 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/36\">",
"       36",
"      </a>",
"      ]. This abnormality more often results in vomiting because of the absence of peristaltic forces in the small intestine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is increasing evidence that several mechanisms of antral motor dysfunction frequently coexist in patients with diseases that cause gastric stasis or pharmacologic models of stasis. These mechanisms include antral hypomotility, \"pylorospasm\" or isolated pyloric pressure waves (IPPW), and failure of proximal gastric contraction; the last abnormality inhibits the redistribution of intragastric content for trituration by the antral segment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/37\">",
"       37",
"      </a>",
"      ]. Diabetes mellitus and scleroderma are examples of diseases that may affect multiple areas of antral function (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51540 \" href=\"UTD.htm?13/12/13509\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Abnormal electrical slow wave rhythms in the stomach may result in reduced antral motor function. The normal pacemaker function of three contractions per minute is replaced by a reduced (bradygastria) or increased (tachygastria) frequency, or a mixed bradytachygastria (",
"      <a class=\"graphic graphic_figure graphicRef66624 \" href=\"UTD.htm?40/18/41262\">",
"       figure 4",
"      </a>",
"      ). These rhythm alterations have been measured intraoperatively in patients with gastric atony, in vitro in muscle strips prepared from atonic stomachs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/38\">",
"       38",
"      </a>",
"      ], and in vivo in a number of disease states including diabetic gastroparesis, anorexia nervosa, motion sickness, and vomiting of pregnancy. The precise mechanism for these dysrhythmias is unclear; prostaglandins have been implicated since prostaglandin synthesis inhibitors restore normal electrical control activity both in vitro and in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other abnormalities that may result in impaired antral function are autonomic neuropathy and hyperglycemia in patients with diabetes mellitus. The concept of \"autovagotomy\" in diabetes was introduced in the late 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/40\">",
"     40",
"    </a>",
"    ]. Gastric acid secretion in response to a swallowed meal was normal in this initial review, suggesting intact parietal cell function; however, the acid secretory response to modified sham feeding (chewing but not swallowing a meal, which is a normally potent vagal stimulus) was reduced. Subsequent morphologic studies of the vagus nerve and enteric nervous system were normal in a report of patients with diabetic gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/41\">",
"     41",
"    </a>",
"    ]. Nevertheless, the clinical association with autonomic and, particularly, vagal dysfunction is frequent in both type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have suggested a role for hyperglycemia in the pathogenesis of antral dysfunction. Acute hyperglycemia can significantly slow gastric motility and the emptying of solids in normals and patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In one study of normal subjects, for example, gastric contractions were nearly absent at a serum glucose concentration of 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and were markedly reduced at concentrations of 140 and 175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 and 9.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/44\">",
"     44",
"    </a>",
"    ]. However, even physiologic changes in blood glucose within the normal postprandial range can increase gastric retention of a solid meal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link&amp;anchor=H4#H4\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\", section on 'Gastroparesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of chronic hyperglycemia is less clear. In one study of 87 randomly selected diabetic patients, gastric emptying of a liquid meal was slower in those with blood glucose values above 270",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there are no data showing that a chronic improvement in glycemic control enhances gastric emptying. Furthermore, the precise contribution of chronic hyperglycemia in diabetics, separate from the effects of simultaneous autonomic dysfunction, remains uncertain.",
"   </p>",
"   <p>",
"    Experimental models of gastroparesis show a reduction or remodeling in the number of ICC in the deep muscle plexus. This leads to secondary effects in gastric muscles because of the lack of trophic factors (eg, stem cell factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. There are a few case reports documenting the same deficiency in patients with gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of ICC results from imbalance between the processes that injure ICC networks and processes that generate and maintain ICC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/53\">",
"     53",
"    </a>",
"    ]. The relative insulinopenia and IGF-1 deficiency in diabetes leads to reduced production of smooth muscle cell-produced stem cell factor, an important ICC survival factor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/48\">",
"     48",
"    </a>",
"    ]. Diabetes is associated with high oxidative stress which may result from upregulation of macrophage heme oxygenase-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     The pylorus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two disease processes have been associated with pyloric dysfunction: idiopathic hypertrophic pyloric stenosis; and diabetic gastroparesis. In the former, a deficiency of inhibitory nitric oxide-containing neurons leads to lack of relaxation or excessive spasm. In diabetes mellitus, excessive tonic and phasic pressure activity at the level of the pylorus is present, contrasting with the postprandial antral hypomotility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/55\">",
"     55",
"    </a>",
"    ]. Experimental evidence suggests that normalization of blood glucose with insulin treatment or treatment with the phosphodiesterase-5 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    restores normal gastric emptying of liquids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise contribution of the pylorus alone to impaired gastric emptying in disease is unclear. However, this may be a moot point since, in most diseases and in pharmacologic models of gastric stasis, excessive pyloric contractility is most often associated with significant impairment of antral and probably fundal contractility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Abnormal small bowel motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in small bowel motility can result in delayed gastric emptying of solids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/56\">",
"     56",
"    </a>",
"    ]. This is true regardless of whether the underlying process is neuropathic or myopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/57\">",
"     57",
"    </a>",
"    ]. Disturbances of intestinal ICCs can also affect the small bowel and result in impaired gastric emptying (eg, in paraneoplastic dysmotility) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14312/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/60/8130?source=see_link\">",
"       \"Patient information: Gastroparesis (delayed gastric emptying) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452462360\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The motor function of the gut is controlled at three main levels: the parasympathetic and sympathetic nervous systems, enteric neurons and interstitial cells of Cajal, and smooth muscle cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Control of gut motor function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The peristaltic reflex is responsible for propulsion of food from the stomach into the intestine. The peristaltic reflex includes ascending contraction above the level of luminal stimulation, usually due to distention by a food bolus, and descending inhibition below the level of distention. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Peristaltic reflex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stomach has two functional segments: the fundus and the antrum. The mid-portion of the greater curvature of the stomach is the functional site of the gastric electrical pacemaker. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Motor functions of the stomach regions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During fasting, the stomach participates in the cyclical activity front that propagates through the gastrointestinal tract and serves as a \"housekeeper,\" propelling nondigestible solid residue towards the colon.",
"      <br/>",
"      <br/>",
"      Postprandially, the fundus relaxes during swallowing to start the process of accommodation in which the stomach assumes reservoir functions, facilitating the initial chemical digestion of food by acid and proteases before transfer toward the antrum. The antrum produces high amplitude contractions resulting in the grinding, mixing, and emptying of solids from the stomach.",
"      <br/>",
"      <br/>",
"      Interdigestive (between meals) antral motor function clears the stomach of undigestible solid particles whose size has not been reduced by trituration.",
"      <br/>",
"      <br/>",
"      The recovery of proximal gastric tone during the postprandial period is associated with gastric emptying, with the driving force being provided by the pressure gradient between the stomach and duodenum. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Motor functions of the stomach regions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed gastric emptying may be due to abnormalities of the fundus (post-vagotomy state, diabetes mellitus, and functional dyspepsia), abnormalities in antroduodenal contraction (low amplitude, frequency, decreased antral motor function or dysfunction), pyloric dysfunction (idiopathic hypertrophic pyloric stenosis and diabetic gastroparesis) or abnormalities in small bowel motility. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis of delayed gastric emptying'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/1\">",
"      Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127:1592.",
"     </a>",
"    </li>",
"    <li>",
"     Camilleri M. Autonomic regulation of gastrointestinal motility. In: Clinical Autonomic Disorders: Evaluation and Management, Low PA (Ed), Little, Brown, Boston 1992. p.125.",
"    </li>",
"    <li>",
"     Berthoug HR, Neuhuber WL. Distribution and morphology of vagal afferents and efferents supplying the digestive system. In: Innervation of the Gut: Pathophysiological Implications, Tache Y, Wingate D, Burks T (Eds), CRC Press, Boca Raton 1993.",
"    </li>",
"    <li>",
"     Llewellyn-Smith IJ, Furness JB, Wilson AJ, et al. Organization and fine structure of enteric ganglia. In: Autonomic Ganglia, Elvin LG (Ed), John Wiley, New York 1983. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/5\">",
"      Gillespie JS, Maxwell JD. Adrenergic innervation of sphincteric and nonsphincteric smooth muscle in the rat intestine. J Histochem Cytochem 1971; 19:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/6\">",
"      Costa M, Gabella G. Adrenergic innervation of the alimentary canal. Z Zellforsch Mikrosk Anat 1971; 122:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/7\">",
"      Costa M, Furness JB. Somatostatin is present in a subpopulation of noradrenergic nerve fibres supplying the intestine. Neuroscience 1984; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/8\">",
"      Furness JB, Morris JL, Gibbins IL, Costa M. Chemical coding of neurons and plurichemical transmission. Annu Rev Pharmacol Toxicol 1989; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/9\">",
"      Lurken MS, Parkman HP, Abell TL, et al. Histological changes in idiopathic and diabetic gastroparesis. [Abstracts of the 3rd International Meeting of Neurogastroenterology and Motility. August 27-30, 2009. Chicago, IL, USA.]. Neurogastroenterol Motil 2009; 21:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/10\">",
"      Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M. The role of nitric oxide (NO) in the human pyloric sphincter. Hepatogastroenterology 1999; 46:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/11\">",
"      Konturek JW, Fischer H, Gromotka PM, et al. Endogenous nitric oxide in the regulation of gastric secretory and motor activity in humans. Aliment Pharmacol Ther 1999; 13:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/12\">",
"      Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000; 106:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/13\">",
"      Tanaka M, Sarr MG, Van Lier Ribbink JA. Gastrointestinal motor patterns: motilin as a coordinating factor. J Surg Res 1989; 47:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/14\">",
"      Kellow JE, Borody TJ, Phillips SF, et al. Human interdigestive motility: variations in patterns from esophagus to colon. Gastroenterology 1986; 91:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/15\">",
"      Wilson P, Perdikis G, Hinder RA, et al. Prolonged ambulatory antroduodenal manometry in humans. Am J Gastroenterol 1994; 89:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/16\">",
"      Azpiroz F, Malagelada JR. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology 1987; 92:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/17\">",
"      Meyer JH, Thomson JB, Cohen MB, et al. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology 1979; 76:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/18\">",
"      Camilleri M, Malagelada JR, Brown ML, et al. Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol 1985; 249:G580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/19\">",
"      Fich A, Neri M, Camilleri M, et al. Stasis syndromes following gastric surgery: clinical and motility features of 60 symptomatic patients. J Clin Gastroenterol 1990; 12:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/20\">",
"      Bredenoord AJ, Chial HJ, Camilleri M, et al. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/21\">",
"      Kumar A, Attaluri A, Hashmi S, et al. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008; 20:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/22\">",
"      Samsom M, Salet GA, Roelofs JM, et al. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig Dis Sci 1995; 40:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/23\">",
"      Samsom M, Roelofs JM, Akkermans LM, et al. Proximal gastric motor activity in response to a liquid meal in type I diabetes mellitus with autonomic neuropathy. Dig Dis Sci 1998; 43:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/24\">",
"      Delgado-Aros S, Vella A, Camilleri M, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 2003; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/25\">",
"      Takahashi T, Owyang C. Characterization of vagal pathways mediating gastric accommodation reflex in rats. J Physiol 1997; 504 ( Pt 2):479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/26\">",
"      Frank JW, Saslow SB, Camilleri M, et al. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/27\">",
"      Takahashi T, Nakamura K, Itoh H, et al. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997; 113:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/28\">",
"      Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/29\">",
"      Matsuo H, Van Cutsem E, Wilmer A, et al. Impaired gastric compliance is related to weight loss in severe motility-like dyspeptic patients. Gastroenterology 1994; 106:A537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/30\">",
"      Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/31\">",
"      Di Lorenzo C, Youssef NN, Sigurdsson L, et al. Visceral hyperalgesia in children with functional abdominal pain. J Pediatr 2001; 139:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/32\">",
"      Chitkara DK, Camilleri M, Zinsmeister AR, et al. Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr 2005; 146:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/33\">",
"      Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/34\">",
"      Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/35\">",
"      Thumshirn M, Bruninga K, Camilleri M. Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. Am J Gastroenterol 1997; 92:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/36\">",
"      Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998; 93:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/37\">",
"      Heddle R, Collins PJ, Dent J, et al. Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. J Gastroenterol Hepatol 1989; 4:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/38\">",
"      Telander RL, Morgan KG, Kreulen DL, et al. Human gastric atony with tachygastria and gastric retention. Gastroenterology 1978; 75:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/39\">",
"      Sanders KM. Role of prostaglandins in regulating gastric motility. Am J Physiol 1984; 247:G117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/40\">",
"      Feldman M, Corbett DB, Ramsey EJ, et al. Abnormal gastric function in longstanding, insulin-dependent diabetic patients. Gastroenterology 1979; 77:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/41\">",
"      Yoshida MM, Schuffler MD, Sumi SM. There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. Gastroenterology 1988; 94:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/42\">",
"      Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/43\">",
"      Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/44\">",
"      Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/45\">",
"      Schvarcz E, Palm&eacute;r M, Aman J, et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/46\">",
"      Ord&ouml;g T, Takayama I, Cheung WK, et al. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000; 49:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/47\">",
"      Horv&aacute;th VJ, Vittal H, Ord&ouml;g T. Reduced insulin and IGF-I signaling, not hyperglycemia, underlies the diabetes-associated depletion of interstitial cells of Cajal in the murine stomach. Diabetes 2005; 54:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/48\">",
"      Horv&aacute;th VJ, Vittal H, L&ouml;rincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology 2006; 130:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/49\">",
"      Z&aacute;rate N, Mearin F, Wang XY, et al. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut 2003; 52:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/50\">",
"      Forster J, Damjanov I, Lin Z, et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg 2005; 9:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/51\">",
"      Iwasaki H, Kajimura M, Osawa S, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol 2006; 41:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/52\">",
"      Battaglia E, Bassotti G, Bellone G, et al. Loss of interstitial cells of Cajal network in severe idiopathic gastroparesis. World J Gastroenterol 2006; 12:6172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/53\">",
"      Farrugia G. Interstitial cells of Cajal in health and disease. Neurogastroenterol Motil 2008; 20 Suppl 1:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/54\">",
"      Choi KM, Gibbons SJ, Nguyen TV, et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008; 135:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/55\">",
"      Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/56\">",
"      Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986; 91:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/57\">",
"      Greydanus MP, Camilleri M, Colemont LJ, et al. Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. Gastroenterology 1990; 99:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14312/abstract/58\">",
"      Pardi DS, Miller SM, Miller DL, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002; 97:1828.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2638 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14312=[""].join("\n");
var outline_f13_62_14312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H452462360\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PHYSIOLOGY OF GASTRIC MOTOR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Control of gut motor function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Autonomic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Enteric nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Smooth muscle cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peristaltic reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Motor functions of the stomach regions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS OF DELAYED GASTRIC EMPTYING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormalities of the fundus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postvagotomy gastric motor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Motility disturbances in functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The antrum and antroduodenal coordination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      The pylorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Abnormal small bowel motility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H452462360\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2638|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/12/13509\" title=\"diagnostic image 1\">",
"      Manometry PSS DM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2638|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/51/817\" title=\"figure 1\">",
"      Control of gastric motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/37/2645\" title=\"figure 2\">",
"      Fasting and postprandial gastrointestinal motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/44/43716\" title=\"figure 3\">",
"      Causes of nonulcer dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/18/41262\" title=\"figure 4\">",
"      Tachygastria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/60/8130?source=related_link\">",
"      Patient information: Gastroparesis (delayed gastric emptying) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_62_14313="Treatment of autoimmune hemolytic anemia: Warm agglutinins";
var content_f13_62_14313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14313/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14313/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/62/14313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia (AIHA) due to the presence of warm agglutinins is almost always due to IgG antibodies that react with protein antigens on the red blood cell (RBC) surface at body temperature. For this reason, they are called \"warm agglutinins\" even though they seldom directly agglutinate the RBCs.",
"   </p>",
"   <p>",
"    The clinical syndrome of AIHA may become life-threatening when severe anemia is present. If the hemoglobin falls below a level able to sustain sufficient oxygenation, the patient may become lethargic, confused, and dyspneic with tachycardia. In such patients, corrective measures must be taken at once (eg, corticosteroids, intravenous immunoglobulin, transfusion). If not corrected, death from pulmonary edema, myocardial infarction, or terminal cardiac arrhythmia is inevitable.",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of AIHA due to warm agglutinins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pathogenesis, clinical features, and diagnosis of AIHA due to warm agglutinins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of warm AIHA in patients with systemic lupus erythematosus is discussed separately, although the treatment approach is quite similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of warm agglutinin AIHA varies with age. In children, AIHA is usually a self-limited disease, arising one to three weeks after a viral infection and disappearing within one to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    .) In adults, the disease is usually chronic and may be variably manifest for months to years. The patient should be told of the chronic nature of this disease at the time of diagnosis, since the subsequent course may be complex and protracted.",
"   </p>",
"   <p>",
"    Of importance, AIHA can present as a medical emergency in some patients, especially those with underlying cardiac disease. Immediate transfusion of blood, which requires urgent discussion with blood bank personnel, can be life-saving. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Red blood cell transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of warm agglutinin AIHA is aimed at either reducing the amount of antibody being produced or reducing its efficiency in destruction of the red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/5\">",
"     5",
"    </a>",
"    ]. These objectives are often pursued at the same time and success in treatment of warm agglutinin AIHA (about 95 percent of the time) depends upon the successful balancing of the several means available. Success does not mean cure, since there is usually evidence of persistent activity of the underlying process. Rather, it means control of the degree of anemia sufficient for most activities without excessive compromise of immunologic responsiveness.",
"   </p>",
"   <p>",
"    Treatment should also be aimed at cessation of any possible offending drug (eg, penicillin) and at any underlying disease that might be present, such as systemic lupus erythematosus or chronic lymphocytic leukemia. An extensive list of drugs associated with immune hemolytic anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a positive direct Coombs test is available (",
"    <a class=\"graphic graphic_table graphicRef75322 \" href=\"UTD.htm?13/39/13950\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Monitoring disease response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of hemolysis and response to treatment can be serially monitored by use of those laboratory tests initially employed for establishing the presence of hemolysis (eg, LDH, haptoglobin, indirect bilirubin, Coombs test). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REDUCTION IN ANTIBODY PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two means of reduction of antibody production are available in warm agglutinin AIHA: corticosteroids and cytotoxic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There is also a limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are frequently used as the first therapy for warm AIHA, as they induce remission of antibody production in about 60 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The initial doses used are usually quite high (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent in adults). Doses in children are generally similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H34#H34\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Corticosteroids'",
"    </a>",
"    .) The minimal prednisone dose capable of inducing remission has never been established.",
"   </p>",
"   <p>",
"    When successful, the effect on antibody production, manifest by a rising hemoglobin concentration, is usually seen within one to three weeks. How corticosteroids act in this setting is not clear; some have suggested that the simultaneous presence of steroid in its receptor and the antigen in its receptor induces apoptosis of specifically-programmed T-cells.",
"   </p>",
"   <p>",
"    Once remission has been achieved, the steroid dose must be tapered. In children, this can be done quite rapidly since the disease process is often self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In adults, tapering should be more gradual in an attempt to find the lowest dose that will maintain an adequate remission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7\">",
"     7",
"    </a>",
"    ]. This process must take into account the fact that evidence of an insufficient dose will not be apparent for three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/10\">",
"     10",
"    </a>",
"    ]. Based on our experience, we have found the following schedule to be useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a sufficient hemoglobin concentration (usually &gt;10",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      has been achieved, maintain the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose at 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week.",
"     </li>",
"     <li>",
"      Rapidly taper the dose to 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over a period of two weeks. This is the largest dose that will be tolerable over time. Maintain this dose for one month.",
"     </li>",
"     <li>",
"      If remission persists, gradually reduce the dose on alternate days to 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Maintain this regimen for one month.",
"     </li>",
"     <li>",
"      If remission persists, omit the dose on alternate days while maintaining the dose at 20 mg every other day.",
"     </li>",
"     <li>",
"      If remission persists, reduce the dose to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      on alternate days. Tapering of glucocorticoids should be continued as long as the hemoglobin and haptoglobin levels remain improved and stable, lactate dehydrogenase levels stay low, and the absolute reticulocyte count remains below",
"      <span class=\"nowrap\">",
"       100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Glucocorticoids can be stopped when there is normalization of the hemoglobin, haptoglobin, LDH, and absolute reticulocyte count, although the Coombs&rsquo; test may remain positive. The patient should be monitored for recurrence for a number of months following cessation of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If, at any time during this dose tapering process, the remission is not maintained, other measures (cytotoxic therapy or splenectomy) must be instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7\">",
"     7",
"    </a>",
"    ]. This approach is also warranted in patients who show no response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    after two to three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunosuppressive and cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with other immunosuppressive or cytotoxic drugs (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) also reduces the production of antibody and raises the hemoglobin concentration in patients with warm agglutinin AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7,8,11\">",
"     7,8,11",
"    </a>",
"    ]. General indications for their use are lack of response to or inability to tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or the necessity for a maintenance prednisone dose &gt;15 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These drugs are usually given orally in daily doses, although intravenous pulse dosing has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. They generally take at least one month to be effective; if no effect is seen in four months, further therapy is unlikely to be effective. A common error is to use and persist with a fixed, inadequate dose of these agents. The dose should be adjusted to produce a fall in the total white blood cell count to about",
"    <span class=\"nowrap\">",
"     3000/microL.",
"    </span>",
"    If the dose is reduced after remission to insufficient levels, a falling hematocrit and increased reticulocytes, due to recrudescence of hemolysis, may not be seen for three to four months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    has fewer side effects but may be somewhat less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. It is given in an initial oral dose of 100 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (reduced appropriately for children), which generally does not reduce the reticulocyte count or other blood cell counts by direct toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is given in initial doses of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth or 500 to 700 mg intravenously every three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/8,9,12,13\">",
"     8,9,12,13",
"    </a>",
"    ]. Although cyclophosphamide may be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , it has numerous side effects including hair loss, gonadal toxicity, bone marrow suppression, bladder irritation with hematuria, and development of myelodysplastic syndrome or leukemia. Bladder irritation can be minimized by giving the medication as a single dose in the morning, increasing urinary output during the day, and voiding before retiring to bed at night, or by intravenous pulse therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , in doses that have been used to treat refractory aplastic anemia (ie, 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV for four days along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    and G-CSF) produced the anticipated severe and prolonged neutropenia, but produced remissions in six of nine patients with refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclosporine and mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (Cyclosporin A, starting oral dose 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses, with subsequent dose adjustment depending on hematologic response, blood pressure, BUN, creatinine, and electrolytes) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF, starting dose 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in two divided oral doses, increasing to 1000 to 2000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are immunosuppressive agents that have been used in some cases of resistant autoimmune disease. Their successful use in patients with AIHA with or without idiopathic thrombocytopenia (Evans syndrome) resistant to standard therapy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cytotoxic drugs have been used to suppress antibody production but are without wide experience. Intravenous vinca alkaloids (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ) may induce a rapid but evanescent remission and may be used while waiting for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to become effective. Vincristine has been delivered attached to platelets, based upon the theory that such \"poison bait\" would be ingested by macrophages; however, there is no clear-cut advantage to this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13064721\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple case studies and retrospective reports have indicated success with use of the monoclonal anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in both adults and children with resistant AIHA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Evans syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/18-27\">",
"     18-27",
"    </a>",
"    ]. A retrospective report described the response to treatment with rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly for four doses in most patients) in 36 patients with refractory AIHA who had received a median of four (range: 1 to 8) previous treatments, 13 of whom had undergone splenectomy. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall and complete response rates were 77 and 61 percent, respectively.",
"     </li>",
"     <li>",
"      For the 22 patients achieving complete remission, treatment response was maintained at 6 and 12 months in 100 and 73 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective study investigated the efficacy, safety, and response duration of",
"    <strong>",
"     reduced",
"    </strong>",
"    doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (100 mg fixed dose weekly for four doses) along with a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initial dose 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 30 days, with a slow taper thereafter) as primary or secondary therapy in 14 patients with warm AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/28\">",
"     28",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After two months of treatment, complete responses (ie, hemoglobin &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with normalization of all hemolytic markers) and partial responses (ie, hemoglobin 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or at least a 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase from baseline with no transfusion requirement) were noted in 79 and 21 percent, respectively.",
"     </li>",
"     <li>",
"      Complete plus partial responses remained at 100 percent at 6 and 12 months. Nine of the 14 patients completely stopped",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      treatment at a median time of 89 days (range: 58 to 150 days).",
"     </li>",
"     <li>",
"      There were no disease relapses during the first 12 months of observation; estimated two-year relapse-free survival was 81 percent.",
"     </li>",
"     <li>",
"      Treatment was well tolerated; no patient experienced the most frequently described infusion-related reactions from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and no infectious, hematologic, or extra-hematologic complications were seen during a median follow-up period of 15 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More experience with this regimen will be needed before it can be recommended as routine treatment in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13064728\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less experience is available with use of the monoclonal anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (Campath-1H), alone or in combination with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which may be associated with disease response but also with profound immunosuppression and development of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , primarily in patients with warm agglutinin AIHA that is either refractory to or has relapsed after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Its main value may be to minimize the prednisone exposure, thereby reducing the incidence of splenectomy. In one series of 17 patients, danazol (initial dose 600 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth) was added to previous regimens or given initially in conjunction with high-dose prednisone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/33\">",
"     33",
"    </a>",
"    ]. Twelve patients showed a rise in hematocrit within one to three weeks. Glucocorticoid therapy was then tapered to a minimum requirement or stopped and, once remission was sustained, the maintenance dose of danazol was reduced to 400 to 600",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REDUCTION IN ANTIBODY EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody",
"    in AIHA destroys the red cells primarily by binding to Fc receptors on effector cells (phagocytes) of the immune system; this occurs most efficiently in the spleen due to close contact of the blood with these cells during the slow circulation through the cords of Billroth (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ). Binding results in phagocytosis (partial or complete) or membrane rupture. When complement is fixed, phagocytic cells in sites other than the spleen are able to bind to the target red cells efficiently.",
"   </p>",
"   <p>",
"    The hemolytic process can be reversed either by removing the primary site of destruction via splenectomy, or by reducing the interaction between splenic macrophages and the antibody-coated RBCs with intravenous immune globulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is probably nearly as efficient as corticosteroids in reducing hemolysis in patients with AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/7\">",
"     7",
"    </a>",
"    ]. About 60 to 70 percent of patients show improvement in the anemia, usually evident within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In about one-half of those that achieve remission, corticosteroids in lower doses than necessary before splenectomy are required to maintain the remission. Splenectomy can be performed safely by a laparoscopic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intravenous gamma globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike its efficacy in the related disorder idiopathic thrombocytopenia, intravenous immune globulin (IVIG) is only occasionally effective in the treatment of autoimmune hemolytic anemia refractory to conventional therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/5\">",
"     5",
"    </a>",
"    ]; it can also be used as part of the initial regimen to establish control in patients with very severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, very high doses may be required (1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days, which is more than twice the usual dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Only about 40 percent of patients respond [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/37\">",
"     37",
"    </a>",
"    ] and, in those who do, the effect is usually transient unless repeated courses of IGIV are given every three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RED BLOOD CELL TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell transfusion may be required when the hemoglobin falls below a level tolerated by the physiology of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .) Special care must be taken in the testing for compatibility because of the presence of the autoantibody [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It is unlikely that fully compatible blood can be found, since the autoantibody usually reacts with antigens present on the cells of almost all individuals in the donor population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Characteristics of the antigens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Presence of alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of greatest importance, the patient with AIHA should be tested for the presence of co-existing alloantibodies, which may have developed following pregnancies or prior transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Alloantibodies, rather than autoantibodies, may cause major transfusion reactions in such patients if not discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H5#H5\">",
"     \"The incompatible crossmatch\", section on 'Alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the process of sorting out the presence and specificity of an alloantibody in the presence of an autoantibody takes additional time. Thus, if the patient needs to be transfused emergently, transfusion should be given prior to the availability of the results.",
"    <strong>",
"     No patient with AIHA should die because of difficulties in finding blood for transfusion",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Experience indicates that most patients will tolerate even serologically incompatible blood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. One report, for example, described 53 patients who received blood transfusions because of decompensated AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/48\">",
"     48",
"    </a>",
"    ]. No patient had transfusion-related alloimmunization or a definite increase in hemolysis, even when the transfused red cells were serologically incompatible because of free serum autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood bank liaison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discussion of the above-noted issues should be initiated",
"    <strong>",
"     immediately",
"    </strong>",
"    with blood bank personnel in order to minimize delays in providing blood, and to minimize potential misunderstandings concerning the degree to which available blood units are compatible with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/49\">",
"     49",
"    </a>",
"    ]. Nevertheless, the blood bank should always be able to find blood for the patient, with the degree of compatibility increasing as the amount of time given to the blood bank for such testing is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/43,50,51\">",
"     43,50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H15#H15\">",
"     \"The incompatible crossmatch\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H23#H23\">",
"     \"The incompatible crossmatch\", section on 'Clinical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     AIHA IN LUPUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of warm AIHA in patients with systemic lupus erythematosus is discussed separately, although the treatments used are generally quite similar to those presented here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVANS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evans syndrome (ES) refers to the combination of Coombs-positive warm AIHA and immune thrombocytopenia (ITP), although, less commonly, some patients will also have autoimmune neutropenia (15 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52\">",
"     52",
"    </a>",
"    ]. The antibodies that cause hemolysis are different from those that cause platelet destruction. Those causing RBC destruction are directed against a base protein portion of the Rh blood group, while those that destroy platelets are frequently directed against platelet",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa.",
"    </span>",
"   </p>",
"   <p>",
"    Although",
"    many cases are idiopathic in origin, ES has been associated with a number of other conditions in about one-half of the cases, including systemic lupus erythematosus, lymphoproliferative disorders, common variable immunodeficiency, and autoimmune lymphoproliferative syndrome, and may be seen following allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H9#H9\">",
"     \"Apoptosis and autoimmune disease\", section on 'Autoimmune lymphoproliferative syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ES is common in both children and adults, and is often either resistant to standard treatment for AIHA or ITP (eg, glucocorticoids, IVIG, splenectomy), or follows a chronic, relapsing course [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. In one report of 68 patients with this condition, only 32 percent were in remission off treatment at a median follow-up of 4.8 years, and 24 percent had died [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52\">",
"     52",
"    </a>",
"    ]. In this series, treatment was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First line treatment &mdash; All 68 patients received at least one course of treatment with a glucocorticoid (initial dose: 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), with an initial response in over 80 percent. The short-term response to IVIG was 60 percent.",
"     </li>",
"     <li>",
"      Second line treatment &mdash; Almost three-quarters of the patients received second line therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , vinca alkaloids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ). Eleven patients received treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , with initial and long-term responses in nine and seven patients, respectively.",
"     </li>",
"     <li>",
"      Splenectomy &mdash; Splenectomy was performed in 19 patients (28 percent), with initial and long-term responses in 15 and 10 patients, respectively. One patient died of sepsis on day 21 post-splenectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no systematic or randomized studies of the treatment of ES; the available literature consists almost entirely of anecdotal case reports and retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. The following treatments (in addition to glucocorticoids, IVIG, and splenectomy) have been reported as successful in some, but not all, patients with ES:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/21,22,52,57-59\">",
"       21,22,52,57-59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/16,62\">",
"       16,62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/54,66\">",
"       54,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/52,55,67\">",
"       52,55,67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is not sufficient information to choose one of these agents over another, although in the current literature there have been more reports of success following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14313/abstract/2\">",
"     2",
"    </a>",
"    ]. Management of autoimmune lymphoproliferative syndrome (ALPS), which may be present in some patients with ES, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/51/12081?source=see_link\">",
"       \"Patient information: Autoimmune hemolytic anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate diagnosis of warm agglutinin autoimmune hemolytic anemia (AIHA) requires documentation of the presence of red cell destruction (hemolysis) along with demonstration of the presence of an autoantibody or of complement on the surface of the patient's red cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with AIHA present with an acute onset of severe hemolysis with symptomatic anemia, requiring immediate treatment. In patients with underlying cardiac disease, AIHA can present as a medical emergency, requiring immediate packed red cell transfusion. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Red blood cell transfusion'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of symptomatic warm agglutinin AIHA is confirmed, we recommend immediate institution of treatment with corticosteroids over splenectomy or use of other immunosuppressive agents (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Poorly responsive or resistant disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients not responding to corticosteroids, or for those who require large doses of corticosteroids to maintain their response, we suggest elective splenectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients unwilling or unable to undergo splenectomy, or for those who have failed or relapsed following splenectomy, we suggest the institution of immunosuppressive or cytotoxic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). At the present time, there is not sufficient information to choose one of these agents over another, although rituximab appears to be the most promising. A combination of drugs may be necessary. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monoclonal antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunosuppressive and cytotoxic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/1\">",
"      Lechner K, J&auml;ger U. How I treat autoimmune hemolytic anemias in adults. Blood 2010; 116:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/2\">",
"      Crowther M, Chan YL, Garbett IK, et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011; 118:4036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/3\">",
"      Buchanan GR, Boxer LA, Nathan DG. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr 1976; 88:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/4\">",
"      Zupa��ska B, Lawkowicz W, G&oacute;rska B, et al. Autoimmune haemolytic anaemia in children. Br J Haematol 1976; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/5\">",
"      King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol 2005; 42:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/6\">",
"      Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005; 42:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/7\">",
"      Pirofsky B. Immune haemolytic disease: the autoimmune haemolytic anaemias. Clin Haematol 1975; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/8\">",
"      Murphy S, LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol 1976; 13:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/9\">",
"      Zupa��ska B, Sylwestrowicz T, Pawelski S. The results of prolonged treatment of autoimmune haemolytic anaemia. Haematologia (Budap) 1981; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/10\">",
"      Rosse WF. Quantitative immunology of immune hemolytic anemia. I. The fixation of C1 by autoimmune antibody and heterologous anti-IgG antibody. J Clin Invest 1971; 50:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/11\">",
"      Worlledge SM, Brain MC, Cooper AC, et al. Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proc R Soc Med 1968; 61:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/12\">",
"      Panceri R, Fraschini D, Tornotti G, et al. Successful use of high-dose cyclophosphamide in a child with severe autoimmune hemolytic anemia. Haematologica 1992; 77:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/13\">",
"      Silva VA, Seder RH, Weintraub LR. Synchronization of plasma exchange and cyclophosphamide in severe and refractory autoimmune hemolytic anemia. J Clin Apher 1994; 9:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/14\">",
"      Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002; 100:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/15\">",
"      Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996; 93:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/16\">",
"      Liu H, Shao Z, Jing L. [The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome]. Zhonghua Xue Ye Xue Za Zhi 2001; 22:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/17\">",
"      Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/18\">",
"      Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001; 97:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/19\">",
"      D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006; 81:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/20\">",
"      Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/21\">",
"      Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/22\">",
"      Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 2004; 77:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/23\">",
"      Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/24\">",
"      Svahn J, Fioredda F, Calvillo M, et al. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Br J Haematol 2009; 145:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/25\">",
"      Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009; 84:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/26\">",
"      Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009; 266:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/27\">",
"      Pe&ntilde;alver FJ, Alvarez-Larr&aacute;n A, D&iacute;ez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010; 89:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/28\">",
"      Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119:3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/29\">",
"      Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/30\">",
"      Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/31\">",
"      G&oacute;mez-Almaguer D, Solano-Genesta M, Tar&iacute;n-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010; 116:4783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/32\">",
"      Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/33\">",
"      Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993; 83:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/34\">",
"      Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992; 29:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/35\">",
"      Katkhouda N, Hurwitz MB, Rivera RT, et al. Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Ann Surg 1998; 228:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/36\">",
"      Flowers JL, Lefor AT, Steers J, et al. Laparoscopic splenectomy in patients with hematologic diseases. Ann Surg 1996; 224:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/37\">",
"      Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993; 44:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/38\">",
"      Macintyre EA, Linch DC, Macey MG, Newland AC. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/39\">",
"      Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986; 51:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/40\">",
"      Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/41\">",
"      Bj&ouml;rkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 1993; 234:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/42\">",
"      Jefferies LC. Transfusion therapy in autoimmune hemolytic anemia. Hematol Oncol Clin North Am 1994; 8:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/43\">",
"      Petz LD. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 2004; 124:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/44\">",
"      Young PP, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/45\">",
"      Ahrens N, Pruss A, K&auml;hne A, et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 2007; 47:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/46\">",
"      Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/47\">",
"      Garratty G, Petz LD. Approaches to selecting blood for transfusion to patients with autoimmune hemolytic anemia. Transfusion 2002; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/48\">",
"      Salama A, Bergh&ouml;fer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/49\">",
"      Ness PM. How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations? Transfusion 2006; 46:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/50\">",
"      Garratty G, Telen MJ, Petz LD. Red cell antigens as functional molecules and obstacles to transfusion. Hematology Am Soc Hematol Educ Program 2002; :445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/51\">",
"      Petz LD. \"Least incompatible\" units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion 2003; 43:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/52\">",
"      Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009; 114:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/53\">",
"      Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. J Pediatr 1980; 97:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/54\">",
"      Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006; 132:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/55\">",
"      Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 1997; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/56\">",
"      Miller BA, Schultz Beardsley D. Autoimmune pancytopenia of childhood associated with multisystem disease manifestations. J Pediatr 1983; 103:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/57\">",
"      Michel M. [Warm autoimmune hemolytic anemias and Evans syndrome in adults]. Rev Med Interne 2008; 29:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/58\">",
"      Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/59\">",
"      Park CY, Chung CH. A patient with mixed type Evans syndrome: efficacy of rituximab treatment. J Korean Med Sci 2006; 21:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/60\">",
"      Chang DK, Yoo DH, Kim TH, et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin Rheumatol 2001; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/61\">",
"      Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005; 75:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/62\">",
"      Tsudo M, Moriguchi T. [Effective cyclosporine therapy to resistant-Evans syndrome]. Rinsho Ketsueki 1996; 37:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/63\">",
"      Dovat S, Roberts RL, Wakim M, et al. Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine. Bone Marrow Transplant 1999; 24:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/64\">",
"      Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol 2006; 81:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/65\">",
"      Cervera H, Jara LJ, Pizarro S, et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995; 22:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/66\">",
"      Oyama Y, Papadopoulos EB, Miranda M, et al. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001; 28:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14313/abstract/67\">",
"      Ucci G, Ferrando P, Valentini D, Zavallone L. A case of Evans' syndrome in a patient with ulcerative colitis. Dig Liver Dis 2003; 35:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7138 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14313=[""].join("\n");
var outline_f13_62_14313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Monitoring disease response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REDUCTION IN ANTIBODY PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunosuppressive and cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclosporine and mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13064721\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13064728\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Danazol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REDUCTION IN ANTIBODY EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intravenous gamma globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RED BLOOD CELL TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Presence of alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood bank liaison",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      AIHA IN LUPUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVANS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Poorly responsive or resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7138|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/59/26544\" title=\"picture 1\">",
"      Red cells in the spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/39/13950\" title=\"table 1\">",
"      Drugs immune hemolytic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/51/12081?source=related_link\">",
"      Patient information: Autoimmune hemolytic anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_62_14314="Treatment of enterococcal infections";
var content_f13_62_14314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of enterococcal infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Barbara E Murray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/62/14314/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/62/14314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococcal species can cause a variety of infections, including urinary tract infections, bacteremia, endocarditis, and meningitis. The antimicrobial agents available for treatment of enterococcal infection are reviewed here, followed by treatment approaches for clinical syndromes caused by enterococci. Other issues related to enterococci are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20229?source=see_link\">",
"     \"Microbiology of enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Approach to susceptible strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with most streptococci, enterococci are relatively resistant to penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ; even when these cell wall-active agents inhibit enterococci, they often do not kill them, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is even less bactericidal. E. faecium are more resistant to penicillin than E. faecalis (MIC90 &gt;16",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    versus 2 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    respectively); MICs for ampicillin are usually 1 dilution lower than those of penicillin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"     Piperacillin",
"    </a>",
"    activity is similar to that of penicillin, and imipenem has some activity against E. faecalis. Cell wall-active agents with limited or no activity against enterococci include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , ticarcillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , most cephalosporins, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Enterococci are also relatively impermeable to aminoglycosides, and the serum concentrations of aminoglycosides required for bactericidal activity are much higher than can be achieved safely in humans. The simultaneous use of a cell wall-active agent is needed to raise the permeability of the cell so that an intracellular bactericidal aminoglycoside concentration can be achieved without excessive toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/1\">",
"     1",
"    </a>",
"    ]. Bactericidal activity is warranted in clinical circumstances of life threatening infection. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Enterococcal isolates are usually tested for susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , penicillin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Prior to using penicillin or ampicillin for endocarditis or other life threatening enterococcal infections, such as meningitis, the isolate should also be screened for beta-lactamase production with nitrocefin, a chromogenic cephalosporin, even if ampicillin susceptible. Although found only rarely, the presence of beta-lactamase confers resistance to penicillin and ampicillin when large numbers of organisms are present (eg, endocarditis vegetation), even though the organism may test susceptible using standard laboratory inocula.",
"   </p>",
"   <p>",
"    Enterococcal isolates from life threatening infections should also be tested for high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . If the organism is reported as susceptible to high levels of an aminoglycoside (\"SYN-S\" indicates \"susceptible to synergism\"), then it is assumed that synergism will be achieved with that aminoglycoside. Strains that are resistant to high levels of gentamicin are resistant to synergism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , netilmicin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    as well as gentamicin, but some of these strains lack high-level resistance to streptomycin and will demonstrate synergism with that agent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Even for strains lacking high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    and particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    should be avoided. All E. faecium are resistant to synergism with tobramycin due to a species specific aminoglycoside transferase and the majority of E. faecium and E. faecalis fails to show synergism with amikacin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    or penicillin are the preferred cell wall agents;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be substituted only in the setting of beta-lactam resistance or hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/4\">",
"     4",
"    </a>",
"    ]. Combinations of ampicillin or penicillin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    are preferable to vancomycin-aminoglycoside combinations since the latter pose a greater risk of nephrotoxicity. Gentamicin is more convenient since determination of serum gentamicin concentrations is more readily available than serum streptomycin levels. As mentioned above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    are generally avoided, and laboratories do not test these aminoglycosides.",
"   </p>",
"   <p>",
"    Antibiotic regimens and doses for susceptible strains are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef71921 \" href=\"UTD.htm?12/37/12892\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Approach to resistant strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major categories of resistant enterococci include those with high-level penicillin resistance, those with high-level aminoglycoside resistance, and those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High-level penicillin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin/",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    resistance (MIC &ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    may be due to alterations in penicillin binding proteins (PBPs) or, rarely, beta-lactamase production. In the setting of infection due to such organisms,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is the cell wall agent of choice unless resistance is due to beta-lactamase production, in which case",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be used as the cell wall agent. Success with high-dose ampicillin and high-dose ampicillin-sulbactam (in conjunction with aminoglycosides) has been described in case reports (for strains resistant to ampicillin that did not produce beta-lactamase) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regimens and doses for treatment of infections due to enterococci with high-level penicillin resistance are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef59332 \" href=\"UTD.htm?14/56/15244\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     High-level aminoglycoside resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;When synergistic, bactericidal therapy is needed (eg, in the setting of endocarditis), testing of enterococci should include high-level aminoglycoside resistance testing for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , since one agent may have activity even when the other does not. Aminoglycoside monotherapy should never be used, and a cell wall active agent should be combined with an aminoglycoside to which the organism is \"synergism susceptible.\" Aminoglycosides reported as \"SYN-R\" (for \"resistant to synergism\") (or as MIC &ge;500",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of gentamicin or &ge;2000",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of streptomycin) should not be used for treatment; other aminoglycosides should generally be avoided.",
"   </p>",
"   <p>",
"    Combination beta-lactam therapy is an option for treatment of infective endocarditis due to E. faecalis with high-level aminoglycoside resistance to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . Benefit from double beta-lactam combinations may be due to saturation of different penicillin binding protein targets. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    has demonstrated efficacy in experimental endocarditis due to E. faecalis strains that are highly resistant to aminoglycosides. This regimen has also been successful for treatment of E. faecalis endocarditis in humans, although it remains unclear whether efficacy is significantly greater than with ampicillin alone, as success with high-dose ampicillin monotherapy has been described in several case reports as well as in the older literature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regimens and doses for treatment of endocarditis and other infections due to enterococci with high-level aminoglycosides resistance are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H15#H15\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'High-level aminoglycoside or vancomycin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vancomycin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach for treatment of enterococcal infection due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant E. faecium (VRE) is uncertain. Although two agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     quinupristin/dalfopristin)",
"    </span>",
"    have been approved for use for infections caused by vancomycin resistant E. faecium (VRE), the utility of these agents for serious infections like endocarditis is uncertain. The resistance profile of vancomycin-resistant enterococci isolates should be evaluated carefully in conjunction with infectious disease expertise when selecting appropriate therapy for such organisms. Furthermore, the need for treatment of such isolates needs to be assessed in each individual case. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -resistant E. faecium isolates often have concurrent high-level resistance to beta lactams and aminoglycosides. In contrast, vancomycin-resistant E. faecalis are usually susceptible to beta lactams, as are E. gallinarum and E. casseliflavus (which are intrinsically vancomycin resistant). The newer agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    have activity against both vancomycin-resistant E. faecalis and E. faecium, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    has activity against E. faecium only.",
"   </p>",
"   <p>",
"    Regimens for treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60674 \" href=\"UTD.htm?8/22/8557\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Parenteral agents with VRE activity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Linezolid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is a bacteriostatic, synthetic oxazolidinone antibiotic that binds to the peptidyltransferase center of the 50S ribosome, preventing peptide bond formation and thus the addition of new amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/11\">",
"     11",
"    </a>",
"    ]. Cross resistance with other protein synthesis inhibitors has not been demonstrated in enterococci, although a mobile gene, cfr, encoding a methyltransferase that modifies 23S rRNA, confers resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <sup>",
"    </sup>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , pleuromutilins, and streptogramin A, as well as linezolid, has been found in staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Linezolid may be given orally or parenterally. It has high bioavailability after oral administration, and it achieves therapeutic levels in most tissues.",
"   </p>",
"   <p>",
"    Early data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    were obtained in the setting of compassionate use programs. One report describing its compassionate use in nearly 500 patients with VRE infection reported a cure in 81 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/14\">",
"     14",
"    </a>",
"    ]. Another report describing its compassionate use in 85 solid organ transplant recipients with VRE infection (43 with bacteremia) demonstrated resolution of infection in 63 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/15\">",
"     15",
"    </a>",
"    ]. However, linezolid failure and resistance have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Safety concerns limit the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , particularly in the setting of prolonged use. Adverse effects include thrombocytopenia, anemia, lactic acidosis, peripheral neuropathy and ocular toxicity. When administered with serotonergic agents (particularly selective serotonin reuptake inhibitors), linezolid can induce serotonin syndrome due to its inhibition of monoamine oxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thrombocytopenia associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    use appears to occur more frequently in the setting of end-stage renal disease and typically resolves after discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/20\">",
"     20",
"    </a>",
"    ]. Neuropathy (peripheral, and less commonly, optic) as well as lactic acidosis are uncommon but important side effects of linezolid. These side effects usually have been reported in the setting of prolonged linezolid administration. Peripheral neuropathy can be severe and may not resolve after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    dosing is 600 mg every 12 hours orally or intravenously. Blood counts and serum chemistries should be monitored at least weekly during linezolid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Daptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is a cyclic lipopeptide bactericidal antibiotic that causes depolarization of the bacterial cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/24\">",
"     24",
"    </a>",
"    ]. It has been approved by the United States Food and Drug Administration (FDA) for treatment of skin and skin structure infections, including those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -susceptible E. faecalis. Although there were insufficient treatment data to support approval for infections due to vancomycin resistant (VR) E. faecalis infections, daptomycin is likely equally efficacious against these organisms.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    has not been approved by the FDA for E. faecium, some favor the use of daptomycin for treatment of E. faecium infections that are resistant in vitro to approved antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The daptomycin MICs for E. faecium are higher than E. faecalis. There are no FDA-approved daptomycin MIC breakpoints for E. faecium, but the CLSI suggests an MIC &gt;4 is non-susceptible.",
"   </p>",
"   <p>",
"    Approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    dosing is 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily for complicated skin and skin structure infections. Minimum dosing for bloodstream infections is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily; in the setting of bloodstream infections some favor doses of 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily or higher. Doses up to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    appeared to be safe in a small number of volunteers and could be considered for life threatening VRE infections with relatively high MICs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    should be evaluated regularly for clinical evidence of myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/29\">",
"     29",
"    </a>",
"    ]. Serial measurements of serum creatine kinase should be monitored at least weekly; the drug should be discontinued in patients with symptomatic myopathy and CPK &ge;5 times ULN (upper limit of normal) or in asymptomatic patients with CPK &ge;10 times ULN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tigecycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is a glycylcycline antibiotic derived from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    with in vitro activity against many gram-positive pathogens (including MRSA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci, and penicillin-resistant Streptococcus pneumoniae), many gram-negatives (important exceptions include Pseudomonas, Proteus, Providencia and Morganella species), anaerobes and atypical species.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    does not have FDA approval for treatment of VRE, although it has been approved for treatment of complicated skin and skin structure infections (cSSSI) and intraabdominal infections, including infections in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    susceptible E. faecalis were recovered. It appears that VRE would also be susceptible to tigecycline, based on in vitro and animal model data [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given concerns regarding achieving adequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    serum drug concentrations, caution should be used with tigecycline for the treatment of patients with bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/33\">",
"     33",
"    </a>",
"    ]. Appropriate tigecycline dosing is 100 mg IV once, followed by 50 mg IV every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Major adverse effects include nausea and vomiting. Tigecycline is difficult to use for outpatient therapy because of the instability of intravenous preparations.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    may be useful for patients with VRE infection who are intolerant of other agents or when VRE are present along with other pathogens that are susceptible to tigecycline. It may also be useful in the setting of renal insufficiency. Anecdotal reports have used tigecycline with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    for VRE infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Quinupristin-dalfopristin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    is a mixture of streptogramin antibiotics with FDA approval for the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant E. faecium infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/39\">",
"     39",
"    </a>",
"    ]. It has poor activity against E. faecalis due to a species-specific ATP-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Central venous access requirements and adverse effects limit the use of quinupristin-dalfopristin; these include metabolic interactions, severe myalgias, arthralgias, nausea and hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 396 patients with VRE infections treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    (including bacteremia, intraabdominal infections, urinary tract infections, and skin infections), the overall efficacy of quinupristin-dalfopristin (both clinical and bacteriologic success) was 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/42\">",
"     42",
"    </a>",
"    ]. Clinical response to quinupristin-dalfopristin is comparable to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Teicoplanin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teicoplanin is a glycopeptide that is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/44\">",
"     44",
"    </a>",
"    ]. It has in vitro activity against E. gallinarum and E. casseliflavus (VanC VRE) as well as most VanB type VRE, although is rarely active against VanA type VRE. Some VanB VRE mutant strains are constitutively resistant to teicoplanin, or emerge after drug exposure in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In countries where it is available, teicoplanin may be used for treatment of infections due to susceptible enterococci. For patients with normal renal function, it should be administered with a loading dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for serious infections) every 12 hours for three doses followed by 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for serious infections) every 24 hours. The addition of an aminoglycoside (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , in the absence of high-level resistance to one of these drugs) should be considered to reduce the emergence of VanB mutants resistant to teicoplanin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10703436\">",
"    <span class=\"h3\">",
"     Telavancin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/42/27301?source=see_link\">",
"     Telavancin",
"    </a>",
"    is a lipoglycopeptide approved for complicated skin and skin structure infections caused by susceptible gram-positive bacteria, including S. aureus. There are no clinical data regarding use of telavancin for enterococcal infections, but it is about four-fold more potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    against enterococci (eg, the MIC90 is 0.12",
"    <span class=\"nowrap\">",
"     mcg/ml),",
"    </span>",
"    with little to no increase in MICs against VanB strains; for VanA strains, the MIC90 has been reported as 4 to 16",
"    <span class=\"nowrap\">",
"     mcg/ml",
"    </span>",
"    in various studies (versus &gt;256",
"    <span class=\"nowrap\">",
"     mcg/ml",
"    </span>",
"    for vancomycin) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].&nbsp;For an infection with a multi-drug resistant VR E. faecium (eg, resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , and highly resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ), addition of telavancin to another agent(s), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (if not highly resistant) or",
"    <span class=\"nowrap\">",
"     quinupristin/dalfopristin,",
"    </span>",
"    would be a reasonable consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on additional therapeutic combinations for treatment of infections due to VRE are limited. Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      plus fluoroquinolones [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       Quinupristin-dalfopristin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       Quinupristin-dalfopristin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      (100 mg every 12 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      , with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones may be useful for treatment of enterococcal urinary tract infections in some circumstances (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Urinary tract infection'",
"    </a>",
"    below).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    demonstrate in vitro activity against some strains of enterococci, but they are only bacteriostatic against these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Clinical success and failure with chloramphenicol has been described but the toxicity of this agent limits its usefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most enterococci in the United States are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and related macrolides. In addition, although some enterococcal isolates demonstrate in vitro susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    <span class=\"nowrap\">",
"     (TMP/SMX),",
"    </span>",
"    in vivo enterococci can use exogenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and bypass the block in folate synthesis induced by",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/63\">",
"     63",
"    </a>",
"    ]. Therefore,",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    should not be used for treatment of enterococcal infections, even if in vitro susceptibility testing suggests sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important clinical infections due to enterococci include urinary tract and wound infections, bacteremia, endocarditis and meningitis. Urinary tract infections generally do not require bactericidal therapy; monotherapy is sufficient. In the setting of invasive infections such as endocarditis, meningitis and bacteremia (in the setting of valvulopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    critical illness), bactericidal activity is warranted. In such cases synergistic activity of a cell wall-active agent in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    is generally required. Testing for high-level resistance to gentamicin and streptomycin should be performed when combination therapy is indicated (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Approach to susceptible strains'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In general, determining the clinical role of an enterococcus recovered from a patient should be tailored to individual patient circumstances, since isolation of an enterococcus does not always necessarily require targeted therapy. Enterococcus can also be a colonizer (such as in respiratory specimens or urinary catheters), or part of a mixed infection (such as in polymicrobial cultures in the setting of intraabdominal surgery, or traumatic wounds) for which therapy is being administered for a more virulent organism. E. faecalis infections tend to be more virulent than E. faecium and therefore should command greater attention when the clinical significance of culture data is in question.",
"   </p>",
"   <p>",
"    Depending on the nature of the clinical illness, acute infection due to VRE may be treated to resolution, although in some cases colonization may persist indefinitely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary tract is the most common site from which enterococci are recovered; manifestations can include urinary colonization, uncomplicated cystitis, pyelonephritis, perinephric abscess or prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/63\">",
"     63",
"    </a>",
"    ]. Most enterococcal UTIs are nosocomial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with obstruction, urinary catheterization or instrumentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Bacteremia in the setting of enterococcal UTI is relatively uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management should include removal of urinary catheters, if possible; this intervention alone has been observed to resolve enterococcal urinary catheter-associated",
"    <span class=\"nowrap\">",
"     infections/colonization",
"    </span>",
"    in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/71\">",
"     71",
"    </a>",
"    ]. If susceptibility is documented, the best options for oral therapy of enterococcal lower UTIs are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"     fosfomycin",
"    </a>",
"    ; dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef73620 \" href=\"UTD.htm?8/22/8555\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/72\">",
"     72",
"    </a>",
"    ]. Nitrofurantoin achieves excellent therapeutic levels in the urine and renal parenchyma but is not adequate for treatment of infection at other sites. Fosfomycin has FDA approval for treatment of uncomplicated UTIs caused by E. faecalis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    E. coli, although many E. faecium strains are also susceptible to fosfomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    may also be considered (see below).",
"   </p>",
"   <p>",
"    Alternative oral agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    or a fluoroquinolone, although data on their efficacy for the treatment of enterococcal UTIs are limited; the latter should not be used as monotherapy in the setting of systemic infection since achievable serum levels of fluoroquinolones are frequently close to the minimum inhibitory concentrations (MICs) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/75-82\">",
"     75-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     Moxifloxacin",
"    </a>",
"    has better in vitro activity than the earlier fluoroquinolones such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , although moxifloxacin achieves lower urine concentrations. Ciprofloxacin-resistant isolates tend to have relatively high MICs to the new fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with complicated UTI and for patients unable to tolerate oral therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    is the drug of choice. Even for strains with ampicillin MIC &gt;64",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    ampicillin may still be effective since the drug is concentrated in the urine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is an appropriate alternative if the organism is susceptible.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    can be considered for urinary tract infections due to ampicillin- and vancomycin-resistant strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portals of entry for enterococcal bacteremia include the gastrointestinal tract, the urinary tract, intravascular catheters, and wounds (such as ulcers or burns) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/63,84-88\">",
"     63,84-88",
"    </a>",
"    ]. Most cases of enterococcal bacteremia due to species other than E. faecalis are not associated with endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/67,84,86,89-92\">",
"     67,84,86,89-92",
"    </a>",
"    ]. The relative risk of endocarditis in patients with E. faecalis bacteremia is higher, but still relatively low. Septic shock in the setting of enterococcal bacteremia is uncommon and should raise suspicion for a polymicrobial infection with accompanying gram-negative bacilli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Enterococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial therapy for enterococcal bacteremia is warranted in the setting of two or more positive blood cultures, a single positive blood culture accompanied by signs of sepsis, or a single positive blood culture together with a positive enterococcal culture from another usually sterile site. In the setting of a single positive blood culture for an enterococcus, particularly E. faecalis, in a patient with preexisting prosthetic heart valve, some favor initiating treatment while awaiting results of additional blood cultures; others favor withholding therapy pending these results. The optimal duration of therapy is not known; one to two weeks may be appropriate.",
"   </p>",
"   <p>",
"    Many experts favor deferring antimicrobial therapy for enterococcal bacteremia in the setting of a single positive blood culture in the absence of clinical evidence for sepsis, or in patients who have a polymicrobial infection and are receiving appropriate therapy for a more virulent organism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. For circumstances in which an intravascular catheter is the likely source of the bacteremia, catheter removal alone may be sufficient to cure the infection. However, if febrile most patients should be empirically started on antibiotics after detection of enterococcal infection and after additional cultures are obtained; such therapy can generally be discontinued after 5 to 7 days if symptoms have resolved.",
"   </p>",
"   <p>",
"    There is no consensus as to whether the optimal treatment for enterococcal bacteremia consists of monotherapy or combination therapy. Although a number of studies suggest that there is no advantage of combination therapy over monotherapy, some favor combination therapy in the setting of valvulopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    critical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/87,93,95\">",
"     87,93,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for monotherapy and combination therapy are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef71921 \" href=\"UTD.htm?12/37/12892\">",
"     table 1",
"    </a>",
"    ). For monotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    is the agent of choice for susceptible strains.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    may be administered in the setting of beta-lactam resistance or allergy. For combination therapy, which should be administered in the setting of a prosthetic valve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged bacteremia, an aminoglycoside (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or in the setting of resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) should be added. Options for treatment of resistant enterococci are outlined in the Tables (",
"    <a class=\"graphic graphic_table graphicRef59332 \" href=\"UTD.htm?14/56/15244\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60674 \" href=\"UTD.htm?8/22/8557\">",
"     table 3",
"    </a>",
"    ). Data on combination beta lactam regimens for treatment of enterococcal endocarditis is outlined in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H11#H11\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Enterococci'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The optimal duration of antimicrobial therapy for treatment of enterococcal bacteremia is uncertain. For uncomplicated infection, 5 to 7 days of therapy is likely adequate. Therapy should be extended in the setting of sustained high-grade bacteremia and in the setting of a prosthetic valve, even in the absence of echocardiography evidence for vegetation. The duration should reflect presumed endocarditis as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of enterococcal endocarditis is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococci rarely cause meningitis in normal adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/96\">",
"     96",
"    </a>",
"    ]. Most cases of enterococcal meningitis occur in patients with head trauma, neurosurgery, intraventricular or intrathecal catheters, or anatomic defects of the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Rarely, enterococcal meningitis can be a complication of high-grade bacteremia in patients with enterococcal endocarditis or immunodeficiency such as AIDS or hematologic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Enterococcal meningitis is also seen in the setting of neonatal sepsis and has been described in association with strongyloides hyperinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach for treatment of enterococcal meningitis is not certain, although most agree that combination therapy is preferable over monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/96,97,101\">",
"     96,97,101",
"    </a>",
"    ]. Combination therapy options for treatment of meningitis are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef61845 \" href=\"UTD.htm?20/51/21308\">",
"     table 5",
"    </a>",
"    ). For patients failing to respond to systemic antibiotics, intraventricular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    (if E. faecium) may be useful.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    have poor CNS penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of enterococcal meningitis caused by E faecium strains resistant to penicillin, aminoglycosides and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is a difficult challenge; intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    or intravenous plus intraventricular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    are reasonable antibiotic choices, although experience with intraventricular administration is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/103-111\">",
"     103-111",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    has also been administered by the intraventricular route [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/38,102\">",
"     38,102",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    (if susceptible) may also be a useful adjunctive agent;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    should not be used for treatment of enterococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/112-114\">",
"     112-114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=see_link\">",
"       \"Patient information: Vancomycin-resistant enterococci (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enterococci are relatively resistant to the killing effects of cell wall active agents (penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) and are impermeable to aminoglycosides. Therefore, synergistic activity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      (for bactericidal activity) in combination with a cell wall-active agent (to facilitate aminoglycoside cell entry by raising cell permeability) is required for optimal treatment of invasive infections such as endocarditis, meningitis and some cases of bacteremia. Antibiotic regimens and doses for susceptible strains are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef71921 \" href=\"UTD.htm?12/37/12892\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Approach to susceptible strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major categories of resistant enterococci include those with high-level",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      resistance, those with high-level aminoglycoside resistance, and those with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      resistance. Antibiotic regimens are outlined in the Tables (",
"      <a class=\"graphic graphic_table graphicRef59332 \" href=\"UTD.htm?14/56/15244\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60674 \" href=\"UTD.htm?8/22/8557\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/62/14314/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach to resistant strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for oral treatment of enterococcal urinary tract infections are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef73620 \" href=\"UTD.htm?8/22/8555\">",
"       table 4",
"      </a>",
"      ). For susceptible strains we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"       fosfomycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with complicated UTI and for patients unable to tolerate oral therapy, we suggest parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antimicrobial therapy for treatment of two or more positive blood cultures, a single positive blood culture accompanied by signs of sepsis, or a single positive blood culture together with a positive enterococcal culture from another usually sterile site (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Options for monotherapy and combination therapy are outlined in the Tables (",
"      <a class=\"graphic graphic_table graphicRef59332 \" href=\"UTD.htm?14/56/15244\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60674 \" href=\"UTD.htm?8/22/8557\">",
"       table 3",
"      </a>",
"      ). For uncomplicated infection, 5 to 7 days of therapy is usually adequate. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of enterococcal endocarditis is discussed in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"       \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest combination therapy for treatment of enterococcal meningitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Combination therapy options for treatment of meningitis are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef61845 \" href=\"UTD.htm?20/51/21308\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Meningitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/1\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/2\">",
"      Caballero-Granado FJ, Cisneros JM, Luque R, et al. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas. J Clin Microbiol 1998; 36:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/3\">",
"      Antalek MD, Mylotte JM, Lesse AJ, Sellick JA Jr. Clinical and molecular epidemiology of Enterococcus faecalis bacteremia, with special reference to strains with high-level resistance to gentamicin. Clin Infect Dis 1995; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/4\">",
"      Treatment Guidelines. Med Lett 2007; 57:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/5\">",
"      Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/6\">",
"      Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/7\">",
"      Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997; 25:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/8\">",
"      Gavald&agrave; J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/9\">",
"      Gavald&agrave; J, Len O, Mir&oacute; JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/10\">",
"      Jones BL, Ludlam HA, Brown DF. High dose ampicillin for the treatment of high-level aminoglycoside resistant enterococcal endocarditis. J Antimicrob Chemother 1994; 33:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/11\">",
"      Wilson DN, Schluenzen F, Harms JM, et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A 2008; 105:13339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/12\">",
"      Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/13\">",
"      Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/14\">",
"      Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/15\">",
"      El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/16\">",
"      Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003; 37:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/17\">",
"      Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/18\">",
"      Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/19\">",
"      Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/20\">",
"      Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/21\">",
"      Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/22\">",
"      Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/23\">",
"      Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/24\">",
"      Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/25\">",
"      Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/26\">",
"      Vouillamoz J, Moreillon P, Giddey M, Entenza JM. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 2006; 58:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/27\">",
"      Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/28\">",
"      Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/29\">",
"      Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/30\">",
"      Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/31\">",
"      Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/32\">",
"      Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/33\">",
"      Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/34\">",
"      Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5:S341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/35\">",
"      Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/36\">",
"      Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/37\">",
"      Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009; 43:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/38\">",
"      Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010; 29:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/39\">",
"      Batts DH, Lavin BS, Eliopoulos GM. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report. Curr Clin Top Infect Dis 2001; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/40\">",
"      Collins LA, Malanoski GJ, Eliopoulos GM, et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993; 37:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/41\">",
"      Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/42\">",
"      Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/43\">",
"      Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004; 53:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/44\">",
"      Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2:ii5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/45\">",
"      Baptista M, Depardieu F, Reynolds P, et al. Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci. Mol Microbiol 1997; 25:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/46\">",
"      Kawalec M, Gniadkowski M, Kedzierska J, et al. Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 2001; 39:4274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/47\">",
"      B&eacute;renger R, Bourdon N, Auzou M, et al. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect 2011; 41:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/48\">",
"      Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008; 62:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/49\">",
"      Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/50\">",
"      Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003; 96:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/51\">",
"      Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004; 38:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/52\">",
"      Tripodi MF, Locatelli A, Adinolfi LE, et al. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998; 17:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/53\">",
"      Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998; 27:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/54\">",
"      Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001; 45:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/55\">",
"      Safdar A, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002; 34:E61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/56\">",
"      Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/57\">",
"      Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005; 41:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/58\">",
"      Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/59\">",
"      Howe RA, Robson M, Oakhill A, et al. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997; 40:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/60\">",
"      Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/61\">",
"      Norris AH, Reilly JP, Edelstein PH, et al. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/62\">",
"      Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/63\">",
"      Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/64\">",
"      Hamilton-Miller JM. Reversal of activity of trimethoprim against gram-positive cocci by thymidine, thymine and 'folates'. J Antimicrob Chemother 1988; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/65\">",
"      Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/66\">",
"      Goodhart GL. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 1984; 252:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/67\">",
"      Anonymous. National Nosocomial Infections Surveillance (NNIS) report, data summary from January 1990 to May 1999, Issued June 1999. Am J Infect Control 1999; 520:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/68\">",
"      National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. Am J Infect Control 1998; 26:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/69\">",
"      Jones RN, Kugler KC, Pfaller MA, Winokur PL. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn Microbiol Infect Dis 1999; 35:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/70\">",
"      Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis 1983; 148:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/71\">",
"      Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996; 156:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/72\">",
"      Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/73\">",
"      Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/74\">",
"      Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 43:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/75\">",
"      Onrust SV, Lamb HM, Balfour JA. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs 1998; 56:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/76\">",
"      Malinverni R, Glauser MP. Comparative studies of fluoroquinolones in the treatment of urinary tract infections. Rev Infect Dis 1988; 10 Suppl 1:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/77\">",
"      Corrado ML, Hesney M, Struble WE, et al. Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. Eur Urol 1990; 17 Suppl 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/78\">",
"      Zervos MJ, Bacon AE 3rd, Patterson JE, et al. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 1988; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/79\">",
"      Tice AD. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. J Antimicrob Chemother 1999; 43 Suppl A:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/80\">",
"      Stannard AJ, Sharples SJ, Norman PM, Tillotson GS. Ciprofloxacin therapy of urinary tract infections in paraplegic and tetraplegic patients: a bacteriological assessment. J Antimicrob Chemother 1990; 26 Suppl F:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/81\">",
"      Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Diagn Microbiol Infect Dis 1999; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/82\">",
"      Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Chemother 1996; 37:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/83\">",
"      Mart&iacute;nez-Mart&iacute;nez L, Joyanes P, Pascual A, et al. Activity of eight fluoroquinolones against enterococci. Clin Microbiol Infect 1997; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/84\">",
"      Gray J, Marsh PJ, Stewart D, Pedler SJ. Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect 1994; 27:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/85\">",
"      Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/86\">",
"      Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/87\">",
"      Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/88\">",
"      Shlaes DM, Levy J, Wolinsky E. Enterococcal bacteremia without endocarditis. Arch Intern Med 1981; 141:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/89\">",
"      Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/90\">",
"      Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/91\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/92\">",
"      Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/93\">",
"      Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia: analysis of 75 episodes. Rev Infect Dis 1989; 11:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/94\">",
"      Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991; 13:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/95\">",
"      Watanakunakorn C, Patel R. Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin. Clin Infect Dis 1993; 17:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/96\">",
"      Stevenson KB, Murray EW, Sarubbi FA. Enterococcal meningitis: report of four cases and review. Clin Infect Dis 1994; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/97\">",
"      Bayer AS, Seidel JS, Yoshikawa TT, et al. Group D enterococcal meningitis. Clinical and therapeutic considerations with report of three cases and review of the literature. Arch Intern Med 1976; 136:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/98\">",
"      Kurup A, Tee WS, Loo LH, Lin R. Infection of central nervous system by motile Enterococcus: first case report. J Clin Microbiol 2001; 39:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/99\">",
"      Buchino JJ, Ciambarella E, Light I. Systemic group D streptococcal infection in newborn infants. Am J Dis Child 1979; 133:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/100\">",
"      Siegel JD, McCracken GH Jr. Group D streptococcal infections. J Pediatr 1978; 93:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/101\">",
"      Nagai K, Yuge K, Ono E, et al. Enterococcus faecium meningitis in a child. Pediatr Infect Dis J 1994; 13:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/102\">",
"      Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008; 61:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/103\">",
"      Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002; 104:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/104\">",
"      Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist 1995; 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/105\">",
"      Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998; 26:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/106\">",
"      Garey KW, Tesoro E, Muggia V, et al. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy 2001; 21:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/107\">",
"      Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001; 33:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/108\">",
"      Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/109\">",
"      Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/110\">",
"      Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001; 20:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/111\">",
"      Steinmetz MP, Vogelbaum MA, De Georgia MA, et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001; 29:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/112\">",
"      Ryan JL, Pachner A, Andriole VT, Root RK. Enterococcal meningitis: combined vancomycin and rifampin therapy. Am J Med 1980; 68:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/113\">",
"      P&eacute;rez Mato S, Robinson S, B&eacute;gu&eacute; RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr Infect Dis J 1999; 18:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/62/14314/abstract/114\">",
"      Venezio FR, Masters D, O'Keefe P. Enterococcal meningitis: failure of treatment with ampicillin and chloramphenicol. J Infect Dis 1984; 150:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3163 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14314=[""].join("\n");
var outline_f13_62_14314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Approach to susceptible strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Approach to resistant strains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High-level penicillin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - High-level aminoglycoside resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vancomycin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIBIOTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Parenteral agents with VRE activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Linezolid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Daptomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tigecycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Quinupristin-dalfopristin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Teicoplanin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10703436\">",
"      - Telavancin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3163|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/37/12892\" title=\"table 1\">",
"      Parenteral rx enterococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/56/15244\" title=\"table 2\">",
"      Rx EC pcn resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/22/8557\" title=\"table 3\">",
"      Parenteral rx VRE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/22/8555\" title=\"table 4\">",
"      Rx enterococci UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21308\" title=\"table 5\">",
"      Rx enterococci mening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=related_link\">",
"      Mechanisms of antibiotic resistance in enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20229?source=related_link\">",
"      Microbiology of enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=related_link\">",
"      Patient information: Vancomycin-resistant enterococci (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_62_14315="Diagnosis Munchausen by proxy";
var content_f13_62_14315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meadow's guidelines for diagnosis Munchausen syndrome by proxy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Study the history to determine which events are real and which are fabricated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Look for temporal associations between illness events and the mother's behavior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scrutinize the personal, social, and family history that the mother has given",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact other family members",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact the mother's physician about a possible history of Munchausen's or unexplained illnesses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ensure that the hospital laboratory stores samples from the child for possible future screenings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       More carefully monitor mother and child, possibly by video surveillance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider a search of the mother and her possessions for possible poisons or substances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Most important, exclude the mother for a day or two and observe whether the symptoms disappear",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Meadow, R, Arch Dis Childhood 1982; 57:92.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14315=[""].join("\n");
var outline_f13_62_14315=null;
var title_f13_62_14316="Neuro complications of hyperthy";
var content_f13_62_14316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the more common neurologic manifestations of hyperthyroidism and Graves' disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardinal features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive dysfunction",
"       </td>",
"       <td>",
"        Ranges from mild inattention and anxiety to agitated delirium, rarely coma",
"       </td>",
"       <td>",
"        Common, especially with acute and more severe thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"       <td>",
"        Usually generalized tonic clonic seizures that usually occur with encephalopathy in acute thyrotoxicosis",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tremor",
"       </td>",
"       <td>",
"        High frequency, low amplitude",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chorea",
"       </td>",
"       <td>",
"        Unifocal or multifocal, sustained or paroxysmal",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"       <td>",
"        Usually cardioembolic, associated with thyrotoxic-induced atrial fibrillation",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopathy",
"       </td>",
"       <td>",
"        Usually mild proximal muscle weakness with normal serum CK",
"       </td>",
"       <td>",
"        Common, but may be subclinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyneuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Usually an axonal sensory polyneuropathy",
"        </p>",
"        <p>",
"         Rare demyelinating polyneuropathy",
"        </p>",
"       </td>",
"       <td>",
"        Approximately 25 percent, but may be subclinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"       <td>",
"        Perhaps more likely to be ocular rather than generalized",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periodic paralysis",
"       </td>",
"       <td>",
"        Usually associated with hypokalemia",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graves' ophthalmopathy",
"       </td>",
"       <td>",
"        Proptosis, restricted eye movements",
"       </td>",
"       <td>",
"        Approximately 25 percent of patients with Graves' disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14316=[""].join("\n");
var outline_f13_62_14316=null;
var title_f13_62_14317="Electrocardiographic monitoring for syncope";
var content_f13_62_14317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Electrocardiographic monitoring for syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ECG monitoring is indicated in patients who have clinical or ECG features suggesting arrhythmic syncope (listed in the \"Risk stratification for syncope\" table). The duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of syncope:",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; Immediate in-hospital monitoring (in bed or telemetric) is indicated in high risk patients (as defined in the \"Risk stratification for syncope\" table)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; Holter monitoring is indicated in patients who have very frequent syncope or pre-syncope (&ge;one per week)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        &bull; ILR is indicated in:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - An early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high risk criteria, and a high likelihood of recurrence within battery longevity of the device",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - High risk patients (as defined in the \"Risk stratification for syncope\" table) in whom a comprehensive evaluation did not demonstrate a cause of syncope or lead to a specific treatment",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; ILR should be considered to assess the contribution of bradycardia before embarking on cardiac pacing in patients with suspected or certain reflex syncope presenting with frequent or traumatic syncopal episodes",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &bull; External loop recorders should be considered in patients who have an inter-symptom interval &le;four weeks",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ECG monitoring is diagnostic when a correlation between syncope and an arrhythmia (brady- or tachyarrhythmia) is detected",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In the absence of such correlation, ECG monitoring is diagnostic when periods of Mobitz II or III degree AV block or a ventricular pause &gt;3 s (with the possible exception of young trained persons, during sleep, medicated patients, or rate-controlled atrial fibrillation), or rapid prolonged paroxysmal SVT or VT are detected. The absence of arrhythmia during syncope excludes arrhythmic syncope.",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The ECG documentation of pre-syncope without any relevant arrhythmia is not an accurate surrogate for syncope",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymptomatic arrhythmias (other than those listed above) are not an accurate surrogate for syncope",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinus bradycardia (in the absence of syncope) is not an accurate surrogate for syncope",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AV: atrioventricular; ECG: electrocardiogram; ILR: implantable loop recorder; SVT: supraventricular tachyradia; VT: ventricular tachycardia.",
"     <br/>",
"     * Class of recommendation.",
"     <br/>",
"     &Delta; Level of evidence.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14317=[""].join("\n");
var outline_f13_62_14317=null;
var title_f13_62_14318="Consensus sleep diary instructions";
var content_f13_62_14318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F87859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F87859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consensus Sleep Diary Instructions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General instructions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          What is a sleep diary?",
"         </strong>",
"        </p>",
"        A sleep diary is designed to gather information about your daily sleep pattern.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          How often and when do I fill out the sleep diary?",
"         </strong>",
"        </p>",
"        It is necessary for you to complete your sleep diary every day. If possible, the sleep diary should be completed within one hour of getting out of bed in the morning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          What should I do if I miss a day?",
"         </strong>",
"        </p>",
"        If you forget to fill in the diary or are unable to finish it, leave the diary blank for that day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          What if something unusual affects my sleep or how I feel in the daytime?",
"         </strong>",
"        </p>",
"        If your sleep or daytime functioning is affected by some unusual event (such as an illness, or an emergency) you may make brief notes on your diary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          What do the words \"bed\" and \"day\" mean on the diary?",
"         </strong>",
"        </p>",
"        This diary can be used for people who are awake or asleep at unusual times. In the sleep diary, the word \"day\" is the time when you choose or are required to be awake. The term \"bed\" means the place where you usually sleep.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Will answering these questions about my sleep keep me awake?",
"         </strong>",
"        </p>",
"        This is not usually a problem. You should not worry about giving exact times, and you should not watch the clock. Just give your best estimate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sleep diary item instructions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use the guide below to clarify what is being asked for each item of the sleep diary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Date:",
"        </strong>",
"        Write the date of the morning you are filling out the diary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          1. What time did you get into bed?",
"         </strong>",
"        </p>",
"        Write the time that you got into bed. This may not be the time you began \"trying\" to fall asleep.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          2. What time did you try to go to sleep?",
"         </strong>",
"        </p>",
"        Record the time that you began \"trying\" to fall asleep.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          3. How long did it take you to fall asleep?",
"         </strong>",
"        </p>",
"        Beginning at the time you wrote in question 2, how long did it take you to fall asleep?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          4. How many times did you wake up, not counting your final awakening?",
"         </strong>",
"        </p>",
"        How many times did you wake up between the time you first fell asleep and your final awakening?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          5. In total, how long did these awakenings last?",
"         </strong>",
"        </p>",
"        What was the total time you were awake between the time you first fell asleep and your final awakening? For example, if you woke 3 times for 20 minutes, 35 minutes, and 15 minutes, add them all up (20 + 35 + 15 = 70 min or 1 hr and 10 min).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          6a. What time was your final awakening?",
"         </strong>",
"        </p>",
"        Record the last time you woke up in the morning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          6b. After your final awakening, how long did you spend in bed trying to sleep?",
"         </strong>",
"        </p>",
"        After the last time you woke-up (item #6a), how many minutes did you spend in bed trying to sleep? For example, if you woke up at 8 am but continued to try and sleep until 9 am, record 1 hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          6c. Did you wake up earlier than you planned?",
"         </strong>",
"        </p>",
"        If you woke up or were awakened earlier than you planned, check yes. If you woke up at your planned time, check no.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          6d. If yes, how much earlier?",
"         </strong>",
"        </p>",
"        If you answered \"yes\" to question 6c, write the number of minutes you woke up earlier than you had planned on waking up. For example, if you woke up 15 minutes before the alarm went off, record 15 minutes here.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          7. What time did you get out of bed for the day?",
"         </strong>",
"        </p>",
"        What time did you get out of bed with no further attempt at sleeping? This may be different from your final awakening time (eg, you may have woken up at 6:35 am but did not get out of bed to start your day until 7:20 am).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          8. In total, how long did you sleep?",
"         </strong>",
"        </p>",
"        This should just be your best estimate, based on when you went to bed and woke up, how long it took you to fall asleep, and how long you were awake. You do not need to calculate this by adding and subtracting; just give your best estimate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          9. How would you rate the quality of your sleep?",
"         </strong>",
"        </p>",
"        \"Sleep quality\" is your sense of whether your sleep was good or poor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          10. How restful or refreshed did you feel when you woke up for the day?",
"         </strong>",
"        </p>",
"        This refers to how you felt after you were done sleeping for the night, during the first few minutes that you were awake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          11a. How many times did you nap or doze?",
"         </strong>",
"        </p>",
"        A nap is a time you decided to sleep during the day, whether in bed or not in bed. \"Dozing\" is a time you may have nodded off for a few minutes, without meaning to, such as while watching TV. Count all the times you napped or dozed at any time from when you first got out of bed in the morning until you got into bed again at night.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          11b. In total, how long did you nap or doze?",
"         </strong>",
"        </p>",
"        Estimate the total amount of time you spent napping or dozing, in hours and minutes. For instance, if you napped twice, once for 30 minutes and once for 60 minutes, and dozed for 10 minutes, you would answer \"1 hour 40 minutes.\" If you did not nap or doze, write \"N/A\" (not applicable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          12a. How many drinks containing alcohol did you have?",
"         </strong>",
"        </p>",
"        Enter the number of alcoholic drinks you had where 1 drink is defined as one 12 oz beer (can), 5 oz wine, or 1.5 oz liquor (one shot).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          12b. What time was your last drink?",
"         </strong>",
"        </p>",
"        If you had an alcoholic drink yesterday, enter the time of day in hours and minutes of your last drink. If you did not have a drink, write \"N/A\" (not applicable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          13a. How many caffeinated drinks (coffee, tea, soda, energy drinks) did you have?",
"         </strong>",
"        </p>",
"        Enter the number of caffeinated drinks (coffee, tea, soda, energy drinks) you had where for coffee and tea, one drink = 6-8 oz; while for caffeinated soda one drink = 12 oz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          13b. What time was your last caffeinated drink?",
"         </strong>",
"        </p>",
"        If you had a caffeinated drink, enter the time of day in hours and minutes of your last drink. If you did not have a caffeinated drink, write \"N/A\" (not applicable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          14. Did you take any over-the-counter or prescription medication(s) to help you sleep?",
"         </strong>",
"        </p>",
"        If so, list medication(s), dose, and time taken: List the medication name, how much and when you took EACH different medication you took tonight to help you sleep. Include medication available over the counter, prescription medications, and herbals (example: \"Sleepwell 50 mg 11 pm\"). If every night is the same, write \"same\" after the first day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          15. Comments:",
"         </strong>",
"        </p>",
"        If you have anything that you would like to say that is relevant to your sleep feel free to write it here.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14318=[""].join("\n");
var outline_f13_62_14318=null;
var title_f13_62_14319="FISH for MCL";
var content_f13_62_14319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FISH analysis for t(11;14)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    FISH analysis for t(11;14) using a colocalization assay. A normal signal would show two red probes, localizing to the two alleles of the CCND1 gene on chromosome 11 and two green probes localizing to the IGH gene on chromosome 14. In this case of a t(11;14) translocation, the red and green probes are brought in close proximity.",
"    <div class=\"footnotes\">",
"     FITC: fluorescein isothiocyanate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_62_14319=[""].join("\n");
var outline_f13_62_14319=null;
